title: Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab.
authors.affiliation: First Department of Propedeutic Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece. psfikakis@med.uoa.gr
authors.forename: Petros P
authors.initials: PP
authors.lastname: Sfikakis
authors.forename: Nikos
authors.initials: N
authors.lastname: Markomichelakis
authors.forename: George P
authors.initials: GP
authors.lastname: Theodossiadis
authors.forename: Vlassis
authors.initials: V
authors.lastname: Grigoropoulos
authors.forename: Nikos
authors.initials: N
authors.lastname: Katsilambros
authors.forename: Panayiotis G
authors.initials: PG
authors.lastname: Theodossiadis
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000069285:Infliximab; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D008875:Middle Aged; D011446:Prospective Studies; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab